From animal experiments showed that ATM-deficient tumors and ATM inhibitor-treated tumors respond well to radiotherapy and immunotherapy in the typical CRC p-MMR (mismatch repair gene-proficient) tumor model, CT26 tumor model [62, 63], with the best effect observed in the combination groups. This evidence concerns the gene ATM and neoplasm.